Sutent Shows Benefit In Rare Pancreatic Cancer; Pfizer Stops Phase III Early
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer stopped a Phase III trial for its cancer drug Sutent (sunitinib) early after the data safety monitoring board said the compound showed significant benefit in a rare form of pancreatic cancer, the company announced March 12